GET DAILY SIGNALSRadiopharm Theranostics (RADX) Drops -16.6% Over 30 Days as Dilution Weighs on Shares
Key Takeaways
- Radiopharm Theranostics American Depositary Shares (ADSs) declined roughly 16.6% over the last 30 days, from about $1.15 to $0.96, extending a longer multi-month downtrend.
- The decline occurred despite a run of positive clinical news for the company's lead program, RAD101, highlighting how dilutive financing has weighed on investor sentiment.
- Share dilution is a central driver: the company's ordinary share count rose from roughly 3.54 billion to about 4.71 billion between mid-2026 and October 2026.
- Radiopharm maintains a relatively thin cash position against its spending rate and has repeatedly tapped capital markets to fund its radiopharmaceutical pipeline.
- Regulatory momentum is genuine: in early November 2026, the company aligned with the U.S. FDA on a single pivotal Phase 3 trial for RAD101 in brain metastases.
- For more detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Discover curated algorithmic strategies by visiting Trending AI Robots.
Radiopharm Theranostics (RADX) Company Overview
Radiopharm Theranostics Limited is a clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for precision oncology. Headquartered in Australia and dual-listed on the ASX (RAD) and Nasdaq (RADX), the company is building a pipeline spanning small molecules, peptides, and nanobodies attached to medical radioisotopes. Its lead asset, RAD101, is an investigational PET imaging agent targeting fatty acid synthase (FASN) to help distinguish recurrent brain metastases from treatment-related changes. The company also advances therapeutic and diagnostic candidates for breast, lung, pancreatic, and prostate cancers, in part through a joint venture with MD Anderson Cancer Center.
Investors follow RADX for its exposure to the growing radiopharmaceuticals and theranostics market and for its pipeline catalysts, while the stock's micro-cap profile, limited liquidity, and recurring financing needs make it a higher-risk, higher-volatility name. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
RADX Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RADX ADSs fell about 16.6%, declining from roughly $1.15 per ADS to $0.96. The move was choppy rather than linear, with intermittent rebounds that were ultimately outweighed by sustained selling pressure.
The quarterly picture is steeper. From roughly $2.56 per ADS in mid-August 2026, the shares dropped to about $0.96 by early November, a decline of more than 60% over the period. This downward trend stands in contrast to a 52-week range that reached as high as $16.25, underscoring how far the stock has retreated from its prior highs and reflecting both dilution and a broad repricing of a heavily issued, pre-revenue clinical-stage company.
What Drove RADX Stock Price in the Last 30 Days
The most important force behind the recent decline was not a setback in the clinic but rather the weight of equity dilution. Radiopharm completed a concurrent U.S. registered direct offering and an Australian placement with a share purchase plan in mid-2026, and it has continued to register shares and warrants for resale. Between mid-2026 and October 2026, the ordinary share count expanded from roughly 3.54 billion to about 4.71 billion, a meaningful increase that diluted existing holders and created persistent supply overhang in a thinly traded ADS.
Financing needs remain a recurring theme. The company ended its June 2026 quarter with a modest cash balance relative to its clinical-stage spending, and it has relied on successive capital raises to extend its runway. That funding pressure, rather than negative trial data, has been the primary drag on the stock over the last 30 days. One thing that stands out here is how the market has prioritized near-term share supply over pipeline progress.
On the clinical side, the news was largely constructive. Radiopharm reported positive interim Phase 2b data for RAD101, announced positive Phase 1 imaging data for RAD301 in pancreatic cancer, completed its End-of-Phase 2 meeting with the FDA, and ultimately aligned with regulators on a single pivotal Phase 3 trial. Despite these milestones, the shares continued to slide, indicating that financing and dilution dynamics have outweighed favorable pipeline developments in the near term.
What Drove RADX Stock Performance Over the Last Quarter
Over the last quarter, the dominant narrative has been the tension between advancing clinical programs and the cost of funding them. Radiopharm's pipeline has made tangible progress, including an FDA Fast Track designation for RAD101, a manufacturing and distribution partnership with Siemens Healthineers for its Phase 3 supply, and positive data readouts across multiple programs. Analyst coverage also expanded, with H.C. Wainwright initiating a Buy rating. From what I see, this progress shows real execution on the science side.
However, the company's recurring capital raises, warrant exercises, and the registration of shares for resale have steadily expanded the share count while the company remains pre-revenue with ongoing operating losses. Long-term strategic investor Lantheus has participated in prior financings, but the cumulative effect of serial issuance has kept pressure on the ADS price. The result has been a sharp multi-month decline in which clinical progress has not translated into sustained share-price appreciation. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum signals.
RADX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the key variables for RADX are financing and execution. Investors should monitor whether the company secures additional capital and on what terms, as the pace of share issuance and any warrant exercises will directly affect the ADS price and shareholder dilution. Cash runway disclosures in upcoming quarterly reports will be closely watched.
On the clinical front, the planned initiation of the RAD101 Phase 3 trial, expected in the first half of 2027, is a pivotal milestone, as is the continued enrollment of therapeutic programs including RV-01 through the MD Anderson joint venture. Data presentations, such as the RAD101 late-breaking readout at the Society of Neuro-Oncology meeting, could also influence sentiment. As a clinical-stage, pre-revenue company with substantial ongoing losses, RADX remains sensitive to broader risk appetite in the biotech and micro-cap sectors.
Using Tickeron AI Tools for Deeper Analysis
In my own research process, I frequently turn to Tickeron’s AI Trading Bots to explore automated strategies across volatile names like this one. These tools help simulate how different approaches might perform under current market conditions and provide a useful layer of quantitative perspective alongside fundamental review. The platform offers a range of bots with varying time horizons and risk profiles, which I find helpful when evaluating micro-cap biotech exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for RADX turns negative, indicating new downward trend
RADX saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned negative. In 43 of the 46 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RADX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RADX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RADX's RSI Oscillator exited the oversold zone, 8 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for RADX just turned positive on October 13, 2026. Looking at past instances where RADX's MACD turned positive, the stock continued to rise in 11 of 16 cases over the following month. The odds of a continued upward trend are 69%.
Following a +10.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where RADX advanced for three days, in 63 of 79 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RADX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.263) is normal, around the industry mean (3.498). P/E Ratio (-0.051) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. RADX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement